Pharmacy-Based hepatitis c testing could cure more people on opioid therapy

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Over 18 years of age. * Previous or current injecting drug user. * Stable OST dose for greater than 12 weeks prior to study enrolment. * Glecaprevir/pibrentasvir treatment naïve. * Able to voluntarily sign and date an informed consent form prior to initiation of any screening or study specific procedures. * Able to understand and adhere to study visit schedule and all other protocol requirements. Exclusion Criteria: * Female who is pregnant, planning to become pregnant or breastfeeding or unwilling/unable to take appropriate birth control. * Known current HIV infection. * Known current HBV infection. Serological: patients with a positive HBsAg or isolated positive anti-HBC will be excluded from the study and followed up in secondary care. * Previous treatment with glecaprevir/pibrentasvir. * Currently taking any concomitant medication that has a warning of'do not co-administer' with glecaprevir and/or pibrentasvir as defined by the Liverpool Hep drug interactions website and product SmPC. * Clinically significant abnormalities that make candidate unsuitable for this study in the opinion of the investigator including but not limited to: * Uncontrolled cardiac, respiratory, gastrointestinal, hematologic, neurologic, psychiatric or other medical disease or disorder, which is unrelated to existing HCV infection. * History of either current or previous decompensated liver disease or symptoms/signs of decompensation e.g. ascites noted on physical exam, use of beta-blockers for portal hypertension, hepatic encephalopathy or oesophageal variceal bleeding. * Candidate is deemed unsuitable to receive study drugs by the study investigator, for any reason according to clinical judgement. * Unable or unwilling to provide informed consent. * History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs. * Drug-drug Interaction which may have safety concerns with any concomitant medication the patient is receiving including non-prescribed and/or recreational drugs.